CoChat

The DOI matches its Crossref record; 152 of the 153 references it cites were found in a registry or an index; 64 of the 121 sources its claims cite were checked for support.

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

Open access
Jalleh, Ryan J., Talley, Nicholas J., Horowitz, Michael, Nauck, Michael A. · 2026 · Journal of Clinical Investigation

Abstract

GLP-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes (T2D) and obesity, with robust evidence for cardiovascular and renal benefits. Nevertheless, GLP-1RA therapy is associated with a pattern of adverse events affecting their safety and tolerability. Here, we delineate mechanisms potentially leading to adverse responses to GLP-1RAs, describe the impact of side effects on treatment persistence, discuss potential mitigation strategies, and identify areas requiring further studies. Concerns that GLP-1RAs raise the risk for acute pancreatitis and pancreatic cancer have been dispelled by long-term clinical trials. However, GLP-1RAs may confer an increased risk for thyroid cancer. Sight-threatening eye complications resulting from rapid reductions in glycemia may be avoided by retinal screening and ophthalmologic treatment before GLP-1RA initiation. The slowing of gastric emptying with GLP-1RA treatment increases the propensity for retained gastric contents, which could increase the risk of aspiration during upper gastrointestinal endoscopy or general anesthesia. These risks may, however, be elevated in individuals with long-standing T2D even in the absence of GLP-1RA treatment. Improved pharmacovigilance and a more standardized, quantitative assessment of adverse events in clinical trials, particularly in the assessment of gastrointestinal symptoms, would facilitate definition of the benefit-risk relationship for individual medications.

Overview

CoChat Summary

## TL;DR

This is a narrative review of adverse effects associated with GLP-1 receptor agonists (and tirzepatide), emphasizing gastrointestinal tolerability, thyroid and eye safety, and risks in specific populations. The paper argues that several feared harms (notably pancreatitis and pancreatic cancer) have been largely dispelled by longer-term trials, while GI side effects, retained gastric contents, and possible thyroid/ocular risks remain clinically important.

## Key findings

  • In a systematic review of 39 randomized controlled trials in people without diabetes, GLP-1RAs increased risk of nausea, vomiting, diarrhea, and constipation versus placebo; for newer therapies, nausea risk versus placebo was semaglutide RR 2.95 (95% CI 2.61–3.32), tirzepatide RR 2.90 (95% CI 2–4.19), and orforglipron RR 4.77 (95% CI 2.02–11.31).
  • In another systematic review of 38 phase III/IV placebo-controlled trials in T2D, nausea occurred in 19.3% with active treatment versus 6.5% with placebo, and vomiting in 7.6% versus 2% with placebo; 6.5% of GLP-1RA users discontinued due to adverse events versus 3.6% on placebo.
  • GLP-1RAs were associated with increased retained gastric contents: one study reported 56% in GLP-1RA users versus 19% in non-users; three systematic reviews found increased odds of premature endoscopy termination from retained gastric contents (OR 4.5, 5.6, and 13.9), but no review found an increased risk of aspiration pneumonia.
  • The review states that concerns about acute pancreatitis and pancreatic cancer have been “dispelled” by long-term trials, but that GLP-1RAs may confer an increased risk for thyroid cancer and that retinopathy complications can occur with rapid glycemic improvement, especially in people with pre-existing advanced retinopathy.

## Methods

  • Narrative review of GLP-1 receptor agonist safety, covering GI, psychiatric, ocular, thyroid, biliary/pancreatic, and population-specific adverse effects.
  • Synthesizes evidence from systematic reviews, randomized controlled trials, cohort studies, case-control studies, and pharmacovigilance reports, with examples drawn from T2D, obesity, cirrhosis, CKD, older adults, pregnancy, and younger individuals.
  • Main analysis is qualitative synthesis of published studies, reporting relative risks, odds ratios, hazard ratios, and event rates where available; no new primary data collection is described.

## Limitations

  • The paper itself notes that surprisingly little research has comprehensively assessed even common GI adverse events, and that adverse-event documentation is suboptimal, making differences between compounds/preparations hard to appreciate.
  • It also states that many safety signals rely on pharmacovigilance databases and observational studies, which are prone to reporting bias and confounding; this is explicitly stated in the paper.
  • Evident from the text: this is a review, so conclusions depend on the quality and heterogeneity of underlying studies; several sections explicitly say larger, prospective, or dedicated studies are needed to confirm associations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci194740

Cites

152 of 153 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Central mechanisms by which peripheral GLP-1RAs may reduce appetite or induce nausea. Peripheral GLP-1 or GLP-1RAs may interact with appetite-regulating regions of the brain via gaps in the blood-brain barrier (27), via tanycyte uptake (32), or indirectly via the nodose ganglia (29). The effects to slow gastric emptying, induce nausea, and reduce energy intake are independent (34). AgRP, agouti-related peptide; AP, area postrema; ARC, arcuate nucleus; BBB, blood-brain barrier; CART, cocaine- and amphetamine-regulated transcript; H, hypothalamus; lPBN, lateral parabrachial nucleus; NAc, nucleus accumbens; NPY, neuropeptide Y; NTS, nucleus tractus solitarius; POMC, proopiomelanocortin; VTA, ventral tegmental area.
Figure 1 Central mechanisms by which peripheral GLP-1RAs may reduce appetite or induce nausea. Peripheral GLP-1 or GLP-1RAs may interact with appetite-regulating regions of the brain via gaps in the blood-brain barrier (27), via tanycyte uptake (32), or indirectly via the nodose ganglia (29). The effects to slow gastric emptying, induce nausea, and reduce energy intake are independent (34). AgRP, agouti-related peptide; AP, area postrema; ARC, arcuate nucleus; BBB, blood-brain barrier; CART, cocaine- and amphetamine-regulated transcript; H, hypothalamus; lPBN, lateral parabrachial nucleus; NAc, nucleus accumbens; NPY, neuropeptide Y; NTS, nucleus tractus solitarius; POMC, proopiomelanocortin; VTA, ventral tegmental area.CC BY · PubMed Central
Figure 2 GLP-1Rs and thyroid C cells. GLP-1Rs are typically expressed in rodent C cells (83). Some GLP-1Rs are expressed in medullary thyroid cancer (85), but there are almost no GLP-1Rs are in healthy human/primary C cells (84). Accordingly, there may be an increased risk of medullary thyroid cancer with GLP-1RA use in susceptible individuals, but this may not be the case for healthy individuals.
Figure 2 GLP-1Rs and thyroid C cells. GLP-1Rs are typically expressed in rodent C cells (83). Some GLP-1Rs are expressed in medullary thyroid cancer (85), but there are almost no GLP-1Rs are in healthy human/primary C cells (84). Accordingly, there may be an increased risk of medullary thyroid cancer with GLP-1RA use in susceptible individuals, but this may not be the case for healthy individuals.CC BY · PubMed Central
Figure 3 Hypothesized mechanisms for ocular complications associated with GLP-1RA therapy. In the eye, rapid reductions in glycemia due to GLP-1RA use may lead to the progression of diabetic retinopathy (A) or NAION (B). Figure based on Chou et al. (95) and Abdeen and le Roux (98).
Figure 3 Hypothesized mechanisms for ocular complications associated with GLP-1RA therapy. In the eye, rapid reductions in glycemia due to GLP-1RA use may lead to the progression of diabetic retinopathy (A) or NAION (B). Figure based on Chou et al. (95) and Abdeen and le Roux (98).CC BY · PubMed Central

Verification

Claims the paper makes

50 Valid · 3 Not valid · 34 Not checked · 11 Own results and interpretations

56 more claims · 32 with their cited sources checked

Create a free account to see all 98 claims and to verify the 9 references still open.

See all claims — free account
  • It may state two separate claims as one. 31
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Citations

Cites

Show all 153 references

Cited by

See all 40

Metadata

Authors
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A.
Affiliations
  • Royal Adelaide Hospital (AU)
  • University of Newcastle Australia (AU)
  • Universitätsmedizin Greifswald (DE)
Corresponding author
Nauck, Michael A.
Venue
Journal of Clinical Investigation
Published
2026-02-16
Volume
136
Issue
4
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W7128962556
Cited by
40
References
152
Citations by year
2026: 40
FWCI
42.43
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Brown University
  • Australian Diabetes Society
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
GLP-1 receptor agonists, drug safety, adverse events, type 2 diabetes, obesity, acute pancreatitis, pancreatic cancer, thyroid cancer, retinal complications, gastric emptying, aspiration risk, treatment persistence, pharmacovigilance, risk-benefit assessment, gastrointestinal symptoms
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Gastric Emptying, Humans, Hypoglycemic Agents, Obesity, Pancreatic Neoplasms, Pancreatitis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. https://app.cochat.ai/papers/10.1172/jci194740
The paper
Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026). The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications. Journal of Clinical Investigation. https://doi.org/10.1172/jci194740

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.